Health experts say that even as more people are vaccinated and boosted, the corona virus is here to stay. And they warn that future variants will likely keep medical practitioners and researchers on their toes as they work to keep both infections and the severity of infections down.
Their message to the public is, don’t let your guard down.
“Covid is going to be with us for the foreseeable future,” said Dr. William Schaffner, professor of medicine in the Division of Infectious Diseases at Vanderbilt University School of Medicine. “We’re struggling to figure out how we can keep this virus down and minimize its damage, and still at the same time enjoy a reasonably normal life.”
Schaffner was among a panel of speakers for a July 29 media briefing organized by Ethnic Media Services on the latest covid variant, and the mounting questions around the pandemic and vaccine efficacy.
COVID-19 cases, deaths, and hospitalizations are once again on the rise in the US. More than two-thirds of Americans have tested positive for covid, including President Joe Biden, who tested positive for the second time in a case of covid rebound.
The BA5 subvariant of Omicron is now responsible for more than 78% of infections in the country, according to data from the Centers for Disease Control and Prevention (CDC).
But public health experts say the figures could represent a severe undercount, with many people failing to report positive results from at-home tests.
Shaffner stressed that updated vaccines will continue to be an essential part of the broader strategy.
“We need more durable, long-term protection against a broader array of different variants, the ones we know and the ones we don’t know yet,” he said. “We would like vaccines that abort and prevent the actual infection at the surface of the mucous membranes, not just vaccines that protect against serious disease.”
Nasal vaccines, which can be administered via a spray or dropper, are gaining more attention among clinical researchers and could offer another route to increasing vaccination rates. The NovaVax vaccine, recently authorized by the Food and Drug Administration (FDA) was licensed for an initial two-dose series, but not yet for a booster.
Dr. Ben Neuman, professor of biology and chief virologist of the Global Health Research Complex at Texas A&M University, has his doubts.
“NovaVax vaccine is fine, but it’s about two years too late,” he said, adding the drug does not replicate the virus as effectively as other vaccines. “NovaVax has this very delicate spike protein that is transported and protected very carefully; a little bit survives to go into your body… With the mRNA vaccine, you get perfect pristine spikes exactly the way nature intended.”
Neuman noted that to date there have been 15 mutations of the Omicron variant, including the newer BA.5 and BA2.75 subvariants, for which the current vaccines appear less effective.
“We are still vaccinating against the 2019 virus and it is now late 2022,” he said. “We have a problem.”
Nearly a third of Americans remain unvaccinated, while a majority of covid-related deaths are occurring among people 65 and over, including those who have been vaccinated.
Speakers stressed that masks continue to play a critical role in slowing the spread of the virus, particularly for those who are at high risk because of age or underlying conditions.
Currently no state mandates mask wearing in public, though several states still require mask wearing in high risk settings, including hospitals and long-term care facilities.
In April, a federal judge struck down the Biden administration’s mask requirement for public transit, airlines and transportation hubs. The Justice Department is expected to appeal the ruling.
Therapeutics such as PAXLOVID have proven to be effective in preventing more severe diseases, mostly among older adults. And there is a monoclonal antibody that can be given to some people who are resistant to PAXLOVID. But experts insist that vaccines remain the most essential tool to fight the virus.
“We now have too many deaths, like 430 a day,” says Chin-Hong. “We have to manage (the virus) and we have the tools to do that right now,” he concluded.